Cargando…

Medication use among patients with Crohn’s disease or ulcerative colitis before and after the initiation of advanced therapy

BACKGROUND: Although various treatments help reduce abdominal pain, real-world pain medication utilization among patients with Crohn’s disease (CD) or ulcerative colitis (UC) receiving advanced therapies is poorly understood. The aim is to understand the utilization of pain medication 12 months befo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hunter, Theresa, Naegeli, April N., Nguyen, Chi, Shan, Mingyang, Smith, Joseph L., Tan, Hiangkiat, Gottlieb, Klaus, Isenberg, Keith
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2022
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9675977/ https://www.ncbi.nlm.nih.gov/pubmed/36402945 http://dx.doi.org/10.1186/s12876-022-02584-4

Ejemplares similares

Identification of inadequate responders to advanced therapy among commercially-insured adult patients with Crohn’s disease and ulcerative colitis in the United States
por: Gibble, Theresa Hunter, et al.
Publicado: (2023)

Burden of Fatigue Among Patients with Ulcerative Colitis and Crohn’s Disease: Results from a Global Survey of Patients and Gastroenterologists
por: Regueiro, Miguel, et al.
Publicado: (2022)

Rectal Urgency Among Patients With Ulcerative Colitis or Crohn’s Disease: Analyses from a Global Survey
por: Ha, Christina, et al.
Publicado: (2023)

Prevalence and Factors Associated With Fecal Urgency Among Patients With Ulcerative Colitis and Crohn’s Disease in the Study of a Prospective Adult Research Cohort With Inflammatory Bowel Disease
por: Dawwas, Ghadeer K, et al.
Publicado: (2021)

Pain Medication and Corticosteroid Use in Ankylosing Spondylitis, Psoriatic Arthritis, and Rheumatoid Arthritis in the United States: A Retrospective Observational Study
por: Hunter, Theresa, et al.
Publicado: (2021)

Gastritis Associated with Initially Pediatric Crohn's Disease and Ulcerative Colitis
por: Basturk, Ahmet, et al.
Publicado: (2018)

Tofacitinib for ulcerative colitis: results of the prospective Dutch Initiative on Crohn and Colitis (ICC) registry
por: Biemans, Vince B. C., et al.
Publicado: (2020)

Full, Partial, and Modified Permutations of the Mayo Score: Characterizing Clinical and Patient-Reported Outcomes in Ulcerative Colitis Patients
por: Naegeli, April N, et al.
Publicado: (2021)

A qualitative study exploring the health-related quality of life and symptomatic experiences of adults and adolescents with ulcerative colitis
por: Newton, Louise, et al.
Publicado: (2019)

Myositis as an Initial Presentation of Ulcerative Colitis before Gastrointestinal Symptoms
por: Kim, Doo Ri, et al.
Publicado: (2020)

Crohn's disease and ulcerative colitis Surgical management
por: Wilkinson, A J
Publicado: (1996)

Mucosal Barrier in Ulcerative Colitis and Crohn's Disease
por: Dorofeyev, A. E., et al.
Publicado: (2013)

The safety of vedolizumab for ulcerative colitis and Crohn's disease
por: Colombel, Jean-Frédéric, et al.
Publicado: (2017)

Ulcerative Colitis and Crohn's Disease: Similarities and Distinctions
por: Sawyerr, Af M, et al.
Publicado: (1994)

Review of pregnancy in Crohn’s disease and ulcerative colitis
por: Laube, Robyn, et al.
Publicado: (2021)

Clinical Outcome Assessments in Pediatric Patients With Ulcerative Colitis and Crohn’s Disease Receiving Biologics: A Retrospective Cohort Study
por: Hunter, Theresa, et al.
Publicado: (2022)

Exploring Disease Remission and Bowel Urgency Severity Among Adults with Moderate to Severe Ulcerative Colitis: A Qualitative Study
por: Dubinsky, Marla C, et al.
Publicado: (2022)

Impact of Bowel Urgency on Quality of Life and Clinical Outcomes in Patients With Ulcerative Colitis
por: Dubinsky, Marla C, et al.
Publicado: (2022)

Incorporating patient experience into drug development for ulcerative colitis: development of the Urgency Numeric Rating Scale, a patient-reported outcome measure to assess bowel urgency in adults
por: Dubinsky, Marla C., et al.
Publicado: (2022)

Expressing the Differences between Crohn Disease and Ulcerative Colitis
por: Wijmenga, Cisca
Publicado: (2005)

Carbohydrate Intake in the Etiology of Crohn's Disease and Ulcerative Colitis
por: Chan, Simon S. M., et al.
Publicado: (2014)

The Changing Prognosis of Ulcerative Colitis and Crohn Disease by Decades
por: Korelitz, Burton I, et al.
Publicado: (2021)

Diagnosis of Crohn’s disease and ulcerative colitis using the microbiome
por: Kang, Da-Yeon, et al.
Publicado: (2023)

Plasma microRNA Profile Differentiates Crohn’s Colitis From Ulcerative Colitis
por: Netz, Uri, et al.
Publicado: (2018)

Changes in health-related quality of life and associations with improvements in clinical efficacy: a Phase 2 study of mirikizumab in patients with ulcerative colitis
por: Dubinsky, Marla C, et al.
Publicado: (2023)

Is there a role for vedolizumab in the treatment of ulcerative colitis and Crohn’s disease?
por: Gilroy, Leah, et al.
Publicado: (2014)

Crohn’s Disease and Ulcerative Colitis Show Unique Cytokine Profiles
por: Nemeth, Zoltan H, et al.
Publicado: (2017)

Tofacitinib, two-faced Janus in ulcerative colitis and Crohn’s disease?
por: Biemans, Vince BC, et al.
Publicado: (2020)

Development of the symptoms and impacts questionnaire for Crohn's disease and ulcerative colitis
por: Dulai, Parambir S., et al.
Publicado: (2020)

Salivary Stress/Immunological Markers in Crohn’s Disease and Ulcerative Colitis
por: Finamore, Alberto, et al.
Publicado: (2020)

A comparison of diverticulitis in Crohn's disease versus ulcerative colitis
por: Persaud, Alana, et al.
Publicado: (2019)

Gut Microbiota and Metabolic Specificity in Ulcerative Colitis and Crohn's Disease
por: Sankarasubramanian, Jagadesan, et al.
Publicado: (2020)

Prevalence of endodontic infection in patients with Crohn´s disease and ulcerative colitis
por: Poyato-Borrego, Manuel, et al.
Publicado: (2021)

Differentially Expressed miRNAs in Ulcerative Colitis and Crohn’s Disease
por: Yarani, Reza, et al.
Publicado: (2022)

Psychometric evaluation of the Urgency NRS as a new patient-reported outcome measure for patients with ulcerative colitis
por: Dubinsky, Marla C., et al.
Publicado: (2022)

Analysis of Healthcare Resource Utilization and Costs after the Initiation of Biologic Treatment in Patients with Ulcerative Colitis and Crohn’s Disease
por: Perera, Sue, et al.
Publicado: (2018)

Differences in Immunophenotyping of Mucosal Lymphocytes Between Ulcerative Colitis and Crohn’s Disease
por: Lee, Heung Bum, et al.
Publicado: (1997)

MicroRNA signatures differentiate Crohn’s disease from ulcerative colitis
por: Schaefer, Jeremy S, et al.
Publicado: (2015)

Selective biologics for ulcerative colitis and Crohn’s disease – clinical utility of vedolizumab
por: Petkau, Jill MV, et al.
Publicado: (2016)

Population pharmacokinetics‐pharmacodynamics of vedolizumab in patients with ulcerative colitis and Crohn's disease
por: Rosario, M., et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_dqnqb9uv1rldq343j8mj3j0qlu